Physiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in its innovative obese NASH hamster model at the European Incretin Study Group 2022 meeting in Lausanne, Switzerland (Sept. 29th – Oct 1st).
Meet Dr François Briand, our Director of Research and Development during the poster session 7-9pm on September the 29th, poster #PP13.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
About us
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.